Swiss pharmaceutical and medical device company Roche has announced a $550m investment to expand its diagnostics site in Indianapolis by 2030.
The expansion is expected to transform Indianapolis into a hub for manufacturing continuous glucose monitoring (CGM) systems.
Also, it aims to strengthen US production capabilities and improve access to diabetes management tools, enhancing health outcomes for patients both domestically and globally.
The Indianapolis site serves as the North American headquarters for Roche Diagnostics, part of the Roche Group, a leading biotech company.
The proposed expansion will support Roche’s strategy to improve patient care.
Roche Diagnostics North America president and CEO Brad Moore said: “The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires.
“By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide.”
Roche’s Indianapolis campus hosts various operations, including US research and development, laboratories, manufacturing, distribution, IT, and administrative functions.
Currently, the facility produces around 5.2 billion Accu-Chek diabetes test strips annually, as one of two global distribution hubs serving the US market and distribution to 53 countries.
Roche’s investment builds on more than $800m in US investments made at sites since 2015, strengthening its long-term commitment to US operations.
The expansion is anticipated to create hundreds of skilled jobs in manufacturing and thousands of jobs in construction.
Also, the investment would enhance Indiana’s economy while increasing domestic production capabilities and reducing reliance on imports, said Roche.
